JOHNSON & JOHNSON is 52.8x more valuable than MADRIGAL PHARMACEUTICALS, INC. by market capitalization ($574.10 B vs $10.87 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | MDGL | JNJ |
|---|---|---|
| Market cap | $10.87 B | $574.10 B |
| US-listed rank | #898 | #20 |
| Revenue (latest FY) | $958.40M | $94.19B |
| Net income (latest FY) | -$288.28M | $26.80B |
| Net margin | -30.1% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 1,184 | 984 |
JOHNSON & JOHNSON is 52.8x more valuable than MADRIGAL PHARMACEUTICALS, INC. by market capitalization ($574.10 B vs $10.87 B).
In their latest fiscal years, MADRIGAL PHARMACEUTICALS, INC. reported $958.40M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: MADRIGAL PHARMACEUTICALS, INC. and JOHNSON & JOHNSON, or browse the full rankings.